Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Company Overview - Sionna Therapeutics is a biotechnology company focused on developing therapies for cystic fibrosis, aiming to restore cystic fibrosis transmembrane conductance regulator (CFTR) function [5][8] - The company has a market capitalization of $1.62 billion and a net income of -$75.27 million for the trailing twelve months (TTM) [4] - Sionna's stock price increased by 201.8% over the past year, closing at $36.16 on March 27, 2026 [4] Recent Transaction - On March 5, 2026, Chief Legal Officer Jennifer Fitzpatrick sold 10,250 shares of common stock, generating approximately $347,000 in proceeds [2][9] - The shares were sold at a weighted average price of $33.86 after exercising options at $6.11 [9] - This transaction resulted in Fitzpatrick holding no direct common stock, representing a complete turnover of her holdings [7] Clinical Trials and Financial Position - Sionna has two ongoing clinical trials with topline data expected in mid-2026: a Phase 2a trial of SION-719 and a Phase 1 dual combination trial of SION-451 [10] - The company ended 2025 with $310.3 million in cash, which is expected to fund operations into 2028, providing a significant runway for development despite having no revenue yet [10]